Shopping Cart 0
Cart Subtotal
USD 0

Bioverativ Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Bioverativ Inc (Bioverativ) is a biotechnology company that discovers, develops, and markets therapeutics for the treatment of hemophilia, and rare blood disorders. Its product portfolio includes Eloctate, which comprises recombinant antihemophilic factor engineered using Fc fusion technology for the treatment of hemophilia A; and Alprolix, which comprises recombinant coagulation factor IX engineered using Fc fusion technology for the treatment of hemophilia B. The company's pipeline encompasses investigational candidates for the treatment of cold agglutinin disease, hemophilia A, beta thalassemia sickle cell disease, hemophilia B, and Sickle cell disease. Bioverativ sells its products in the US, the European Union (EU), New Zealand, Canada, Australia, Japan, Switzerland, Iceland, Liechtenstein, and Norway. Bioverativ is headquartered in Waltham, Massachusetts, the US.

Bioverativ Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Bioverativ Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Bioverativ Inc, Medical Devices Deals, 2012 to YTD 2018 10

Bioverativ Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Bioverativ Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

True North Therapeutics Raises USD45 Million in Series D Financing 12

True North Therapeutics Raises USD40 Million in Series C Financing 13

True North Therapeutics Raises USD35 Million in Series B Financing 15

True North Therapeutics Raises USD22 Million in Series A Venture Financing 16

Partnerships 18

Bioverativ Enters into Research Agreement with Bicycle Therapeutics 18

Licensing Agreements 19

Bioverativ Enters into Licensing Agreement with Oxford BioMedica 19

Acquisition 20

Sanofi Acquires Bioverativ for USD11.5 Billion in Tender Offer 20

Bioverativ Therapeutics Acquires True North Therapeutics 22

Bioverativ Inc-Key Competitors 23

Bioverativ Inc-Key Employees 24

Bioverativ Inc-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Financial Announcements 26

Feb 13, 2018: Bioverativ Reports Fourth Quarter and Full Year 2017 Performance 26

Oct 26, 2017: Bioverativ Reports Third Quarter 2017 Performance 28

Aug 02, 2017: Bioverativ Reports Second Quarter 2017 Performance 30

May 03, 2017: Bioverativ Reports First Quarter 2017 Results 32

Corporate Communications 34

May 15, 2017: Bioverativ Appoints Geno J. Germano to Company's Board of Directors 34

Mar 02, 2017: Anna Protopapas to Join Bioverativ Board of Directors 35

Government and Public Interest 36

Apr 27, 2018: Therapies Targeting Cancer, Deadly Immune Disorder and Life-Threatening Blood Condition Get Almost USD 32 Million Boost from Stem Cell Agency 36

Product News 38

05/29/2018: Amunix announces report by Bioverativ on unprecedented half-life obtained in patients treated with a novel, long-acting FVIII utilizing Amunix's XTEN technology 38

05/21/2018: Bioverativ Presents Preliminary Phase 1/2a Data on BIVV001, the First Factor VIII Therapy to Break Through the VWF Half-Life Ceiling in Hemophilia A 39

05/14/2018: Bioverativ will highlight commitment to transforming hemophilia care at WFH 2018 world congress 40

Product Approvals 41

Jun 12, 2017: Bioverativ Announces FDA Acceptance of Investigational New Drug Application for BIVV001 to Treat Hemophilia A 41

Clinical Trials 42

Jun 18, 2018: Cold Agglutinin Disease Associated with Greater Than Twofold Increased Risk of Mortality in First Five Years After Diagnosis 42

Mar 06, 2018: Bioverativ Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease 43

Dec 11, 2017: Bioverativ's Investigational BIVV009 Demonstrates Safety, Tolerability and Efficacy in Phase 1b Clinical Trial in Cold Agglutinin Disease (CAgD) Patients 44

Nov 01, 2017: Bioverativ to Present New Data on BIVV009 at ASH 2017 Annual Meeting 46

Jan 10, 2017: True North Provides Corporate Update at J.P. Morgan Healthcare Conference 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48


List Of Figure

List of Figures

Bioverativ Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Bioverativ Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Bioverativ Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Bioverativ Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Bioverativ Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Bioverativ Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Bioverativ Inc, Medical Devices Deals, 2012 to YTD 2018 10

Bioverativ Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

True North Therapeutics Raises USD45 Million in Series D Financing 12

True North Therapeutics Raises USD40 Million in Series C Financing 13

True North Therapeutics Raises USD35 Million in Series B Financing 15

True North Therapeutics Raises USD22 Million in Series A Venture Financing 16

Bioverativ Enters into Research Agreement with Bicycle Therapeutics 18

Bioverativ Enters into Licensing Agreement with Oxford BioMedica 19

Sanofi Acquires Bioverativ for USD11.5 Billion in Tender Offer 20

Bioverativ Therapeutics Acquires True North Therapeutics 22

Bioverativ Inc, Key Competitors 23

Bioverativ Inc, Key Employees 24

Bioverativ Inc, Other Locations 25

Bioverativ Inc, Subsidiaries 25

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Bioverativ Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.